HC Wainwright Forecasts Strong Price Appreciation for Kura Oncology (NASDAQ:KURA) Stock

Kura Oncology (NASDAQ:KURA - Get Free Report) had its price target boosted by equities researchers at HC Wainwright from $32.00 to $37.00 in a report issued on Thursday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. HC Wainwright's price objective would indicate a potential upside of 269.96% from the company's previous close.

A number of other research analysts have also issued reports on the stock. Lifesci Capital upgraded shares of Kura Oncology to a "strong-buy" rating in a research note on Tuesday, October 22nd. Cantor Fitzgerald reiterated an "overweight" rating on shares of Kura Oncology in a research report on Wednesday, November 6th. UBS Group began coverage on Kura Oncology in a report on Thursday, October 24th. They issued a "buy" rating and a $27.00 price target for the company. JMP Securities reaffirmed a "market outperform" rating and set a $32.00 price objective on shares of Kura Oncology in a report on Tuesday. Finally, Wedbush reiterated an "outperform" rating and issued a $37.00 price objective on shares of Kura Oncology in a research report on Monday, November 4th. One analyst has rated the stock with a sell rating, one has issued a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $29.43.

Kura Oncology Stock Performance

Shares of Kura Oncology stock traded down $5.91 during trading hours on Thursday, hitting $10.00. 14,206,791 shares of the company were exchanged, compared to its average volume of 966,754. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. The business has a 50-day moving average of $18.28 and a 200-day moving average of $19.82. Kura Oncology has a 1 year low of $9.06 and a 1 year high of $24.17. The stock has a market capitalization of $777.68 million, a price-to-earnings ratio of -4.45 and a beta of 0.86.

Institutional Trading of Kura Oncology

Several large investors have recently modified their holdings of KURA. nVerses Capital LLC purchased a new position in Kura Oncology during the third quarter worth $25,000. SG Americas Securities LLC acquired a new stake in shares of Kura Oncology during the 1st quarter worth about $110,000. Point72 DIFC Ltd purchased a new stake in shares of Kura Oncology during the third quarter worth about $146,000. Quarry LP acquired a new position in shares of Kura Oncology in the second quarter valued at approximately $196,000. Finally, Erste Asset Management GmbH purchased a new position in shares of Kura Oncology during the third quarter valued at approximately $215,000.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.